Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the submission of an international patent application for generation 3.0 psychedelic compounds to treat mental disorders. This application is part of the company's ongoing collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The patent, developed by Prof. Dmitry Tsvelikhovsky, covers new psychedelic compounds, their preparation methods, and therapeutic uses.
The PCT submission allows Clearmind to proceed with national phase applications in major jurisdictions like the US, Europe, China, and India. Dr. Adi Zuloff-Shani, CEO of Clearmind, emphasized the potential of these advanced molecules to offer improved therapeutic options for patients with mental disorders. Clearmind, a clinical-stage psychedelic pharmaceutical biotech company, focuses on developing novel psychedelic-derived therapeutics for underserved health problems, including alcohol use disorder.
Clearmind Medicine Inc. (Nasdaq: CMND) ha annunciato la presentazione di una domanda di brevetto internazionale per composti psichedelici di generazione 3.0 per il trattamento dei disturbi mentali. Questa domanda fa parte della collaborazione continua dell'azienda con la Yissum Research Development Company dell'Università Ebraica di Gerusalemme. Il brevetto, sviluppato dal Prof. Dmitry Tsvelikhovsky, copre nuovi composti psichedelici, i loro metodi di preparazione e usi terapeutici.
La presentazione PCT consente a Clearmind di procedere con le domande della fase nazionale in giurisdizioni importanti come gli Stati Uniti, Europa, Cina e India. Il Dr. Adi Zuloff-Shani, CEO di Clearmind, ha sottolineato il potenziale di queste molecole avanzate di offrire opzioni terapeutiche migliorate per i pazienti con disturbi mentali. Clearmind, una società biotecnologica farmaceutica psichedelica in fase clinica, si concentra sullo sviluppo di nuove terapie derivate da psichedelici per problemi di salute trascurati, incluso il disturbo da uso di alcol.
Clearmind Medicine Inc. (Nasdaq: CMND) ha anunciado la presentación de una solicitud de patente internacional para compuestos psicodélicos de generación 3.0 para tratar trastornos mentales. Esta solicitud es parte de la colaboración continua de la empresa con la Yissum Research Development Company de la Universidad Hebrea de Jerusalén. La patente, desarrollada por el Prof. Dmitry Tsvelikhovsky, cubre nuevos compuestos psicodélicos, sus métodos de preparación y usos terapéuticos.
La presentación del PCT permite a Clearmind proceder con las solicitudes de fase nacional en jurisdicciones importantes como EE. UU., Europa, China e India. El Dr. Adi Zuloff-Shani, CEO de Clearmind, enfatizó el potencial de estas moléculas avanzadas para ofrecer opciones terapéuticas mejoradas para pacientes con trastornos mentales. Clearmind, una empresa biotecnológica farmacéutica psicodélica en etapa clínica, se enfoca en desarrollar nuevas terapias derivadas de psicodélicos para problemas de salud desatendidos, incluido el trastorno por uso de alcohol.
클리어마인드 메디슨 주식회사(Nasdaq: CMND)는 3세대 환각 화합물에 대한 국제 특허 출원을 발표했습니다. 이는 정신 장애 치료를 위한 것입니다. 이 신청은 예루살렘 히브리 대학교의 이썸 연구 개발 회사와의 진행 중인 협력의 일환입니다. 이 특허는 드미트리 트스벨리코프스키 교수에 의해 개발되었으며, 새로운 환각 화합물과 그 준비 방법 및 치료 용도를 다룹니다.
PCT 출원을 통해 클리어마인드는 미국, 유럽, 중국, 인도와 같은 주요 관할권에서 국가 단계 신청을 진행할 수 있습니다. 클리어마인드의 CEO인 아디 줄로프-샤니 박사는 이러한 고급 분자가 정신 장애 환자에게 향상된 치료 옵션을 제공할 가능성을 강조했습니다. 클리어마인드는 임상 단계의 환각제 제약 생명공학 회사로, 알코올 사용 장애를 포함한 소외된 건강 문제를 위한 새로운 환각제 유래의 치료법 개발에 집중하고 있습니다.
Clearmind Medicine Inc. (Nasdaq: CMND) a annoncé le dépôt d'une demande de brevet international pour des composés psychédéliques de la génération 3.0 destinés à traiter les troubles mentaux. Cette demande fait partie de la collaboration en cours de la société avec la Yissum Research Development Company de l'Université hébraïque de Jérusalem. Le brevet, développé par le Professeur Dmitry Tsvelikhovsky, couvre de nouveaux composés psychédéliques, leurs méthodes de préparation et leurs utilisations thérapeutiques.
Le dépôt PCT permet à Clearmind de procéder aux demandes de phase nationale dans des juridictions majeures telles que les États-Unis, l'Europe, la Chine et l'Inde. Le Dr. Adi Zuloff-Shani, PDG de Clearmind, a souligné le potentiel de ces molécules avancées pour offrir des options thérapeutiques améliorées aux patients souffrant de troubles mentaux. Clearmind, une société de biotechnologie pharmaceutique en phase clinique, se concentre sur le développement de nouvelles thérapies dérivées de psychédéliques pour des problèmes de santé négligés, y compris le trouble lié à l'usage de l'alcool.
Clearmind Medicine Inc. (Nasdaq: CMND) hat die Einreichung eines internationalen Patentantrags für 3.0 Generation psychotropen Verbindungen zur Behandlung von psychischen Störungen angekündigt. Dieser Antrag ist Teil der laufenden Zusammenarbeit des Unternehmens mit der Yissum Research Development Company der Hebräischen Universität Jerusalem. Das Patent, entwickelt von Prof. Dmitry Tsvelikhovsky, umfasst neue psychotrope Verbindungen, deren Herstellungsmethoden und therapeutische Anwendungen.
Die PCT-Einreichung ermöglicht es Clearmind, nationale Phasenanträge in wichtigen Gerichtsbarkeiten wie den USA, Europa, China und Indien zu stellen. Dr. Adi Zuloff-Shani, CEO von Clearmind, betonte das Potenzial dieser fortschrittlichen Moleküle, verbesserte therapeutische Optionen für Patienten mit psychischen Störungen anzubieten. Clearmind, ein biopharmazeutisches Unternehmen im klinischen Stadium, konzentriert sich auf die Entwicklung neuartiger, aus Psychotropen abgeleiteter Therapien für vernachlässigte Gesundheitsprobleme, einschließlich Alkoholmissbrauch.
- Submission of international patent application for generation 3.0 psychedelic compounds
- Potential expansion of intellectual property rights in major global markets
- Collaboration with prestigious research institution (Hebrew University of Jerusalem)
- Development of advanced molecules for treating mental disorders
- Diversification of the company's intellectual property portfolio
- None.
This PCT application for generation 3.0 psychedelic compounds marks a significant step in Clearmind's intellectual property strategy. The move to secure international patent protection could potentially strengthen the company's market position and create barriers to entry for competitors in major markets like the US, Europe, China and India.
However, investors should note that patent applications don't guarantee approval or commercial success. The long and costly process of drug development, coupled with regulatory hurdles in the psychedelic space, presents significant challenges. While this patent could be valuable if approved, it's still early-stage and the path to commercialization remains uncertain.
The development of generation 3.0 psychedelic compounds represents a potential leap forward in treating mental disorders. These advanced molecules could offer improved efficacy and reduced side effects compared to existing treatments. However, it's important to temper expectations as the clinical efficacy and safety profile of these compounds are yet to be established.
The collaboration with Hebrew University adds credibility to Clearmind's research efforts. Still, investors should be aware that the psychedelic therapeutics field is highly competitive, with several companies pursuing similar goals. Clearmind's success will depend on the unique properties of their compounds and their ability to navigate the complex regulatory landscape for psychedelic treatments.
The global mental health treatment market is projected to reach
However, investor enthusiasm should be tempered by the early stage of development and the highly speculative nature of psychedelic therapeutics. While the market potential is significant, Clearmind faces stiff competition from both established pharmaceutical companies and other psychedelic startups. The company's ability to secure funding and advance its pipeline will be important for long-term success.
Vancouver, Canada, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the international Patent Cooperation Treaty (“PCT”) as part of the company’s ongoing collaboration with the with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”) pursuant to the exclusive licensing agreement that the Company entered into with Yissum.
This patent application refers to generation 3.0 of psychedelic compounds, methods of their preparation and uses thereof in the treatment of mental disorders and was developed by Prof. Dmitry Tsvelikhovsky of the Hebrew University of Jerusalem.
The PCT submission will allow the company to proceed to the national phase, which involves submitting applications to regional offices in various countries to seek patent protection in major jurisdictions like the US, Europe, China and India.
Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, "Under the exclusive global license agreement we signed with Yissum, this patent submission, if approved, will secure the intellectual property rights of this important patent for the company. We strongly believe in the potential of psychedelic treatments to become a vital tool in treating, mental disorders and we see Clearmind, as a leading company in the space, continuing to drive innovation. We believe that this next generation psychedelic, featuring new and advanced molecules may offer an excellent therapeutic option to improve quality of life for patients suffering from mental disorders.”
About Yissum
Yissum is the technology transfer company of the Hebrew University of Jerusalem. Founded in 1964, Yissum serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum’s mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. The company has registered more than 11,680 patents globally, licensed over 1,160 technologies, and has spun out over 260 companies. Yissum’s business partners span the globe. For further information please visit www.yissum.co.il.
About Clearmind Medicine Inc.
Clearmind is a clinical- stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses how this patent submission, if approved, will secure the intellectual property rights of this important patent for the company, its belief in the potential of psychedelic treatments to become an important tool in treating, mental disorders and Clearmind, as a leading company in the space, to continue to lead innovation and its belief that this next generation psychedelic, featuring new and advanced molecules may introduce an excellent therapeutic option to improve quality of life for patients suffering from mental disorders. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the latest patent application submitted by Clearmind Medicine (CMND)?
Who developed the new psychedelic compounds for Clearmind Medicine (CMND)?
What are the potential benefits of Clearmind Medicine's (CMND) new psychedelic compounds?
In which markets does Clearmind Medicine (CMND) plan to seek patent protection for its new compounds?
